Almawash S
Cancers (Basel). 2025; 17(5).
PMID: 40075727
PMC: 11899125.
DOI: 10.3390/cancers17050880.
Lingel H, Fischer L, Remstedt S, Kuropka B, Philipsen L, Han I
Cell Death Differ. 2024; 32(3):561-572.
PMID: 39390117
PMC: 11893764.
DOI: 10.1038/s41418-024-01399-y.
Souri Z, Pakdel F
J Ophthalmic Vis Res. 2024; 19(3):368-380.
PMID: 39359534
PMC: 11443990.
DOI: 10.18502/jovr.v19i3.15047.
King H, Lewin S
Immunol Rev. 2024; 328(1):350-371.
PMID: 39248154
PMC: 11659942.
DOI: 10.1111/imr.13388.
Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S
Cancer Cell. 2024; 42(9):1582-1597.e10.
PMID: 39214097
PMC: 11387127.
DOI: 10.1016/j.ccell.2024.08.007.
Resident memory T cells and cancer.
Gavil N, Cheng K, Masopust D
Immunity. 2024; 57(8):1734-1751.
PMID: 39142275
PMC: 11529779.
DOI: 10.1016/j.immuni.2024.06.017.
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).
Davar D, Cavalcante L, Lakhani N, Moser J, Millward M, McKean M
J Immunother Cancer. 2024; 12(8).
PMID: 39097413
PMC: 11344531.
DOI: 10.1136/jitc-2024-009474.
Crosstalk between efferocytic myeloid cells and T-cells and its relevance to atherosclerosis.
Ngai D, Sukka S, Tabas I
Front Immunol. 2024; 15:1403150.
PMID: 38873597
PMC: 11169609.
DOI: 10.3389/fimmu.2024.1403150.
Modulatory Role of Phytochemicals/Natural Products in Cancer Immunotherapy.
Vijayan Y, Sandhu J, Harikumar K
Curr Med Chem. 2024; 31(32):5165-5177.
PMID: 38549529
DOI: 10.2174/0109298673274796240116105555.
Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy.
Ebrahimi N, Abdulwahid A, Mansouri A, Karimi N, Bostani R, Beiranvand S
Cell Mol Life Sci. 2024; 81(1):106.
PMID: 38418707
PMC: 10902086.
DOI: 10.1007/s00018-023-05098-8.
Precision drugs for recurrent or metastatic nasopharyngeal carcinoma (Review).
Liang R
Exp Ther Med. 2023; 26(6):585.
PMID: 38023360
PMC: 10665982.
DOI: 10.3892/etm.2023.12284.
Immune checkpoint inhibitors for multiple myeloma immunotherapy.
Liu Z, Xu X, Liu H, Zhao X, Yang C, Fu R
Exp Hematol Oncol. 2023; 12(1):99.
PMID: 38017516
PMC: 10685608.
DOI: 10.1186/s40164-023-00456-5.
The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8 T-cell immunity.
Yu J, Cui J, Zhang X, Xu H, Chen Z, Li Y
Cell Mol Immunol. 2023; 20(12):1445-1456.
PMID: 37932534
PMC: 10687085.
DOI: 10.1038/s41423-023-01093-y.
Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor-induced kidney disease.
Seethapathy H, Mistry K, Sise M
Immunol Rev. 2023; 318(1):61-69.
PMID: 37482912
PMC: 10865966.
DOI: 10.1111/imr.13243.
Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma.
Zhao L, Shi A, Yang Y, Liu Z, Hu X, Shu L
Front Oncol. 2023; 13:1140103.
PMID: 37064120
PMC: 10090456.
DOI: 10.3389/fonc.2023.1140103.
Cytotoxic T-lymphocyte-associated protein 4 +49A/G polymorphism in Down syndrome children with Hashimoto's thyroiditis.
Faizi M, Rochmah N, Hisbiyah Y, Perwitasari R, Putri Q, Basuki S
Biomol Biomed. 2023; 23(4):634-639.
PMID: 36724016
PMC: 10351086.
DOI: 10.17305/bb.2022.7869.
In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways.
Abdeladhim M, Karnell J, Rieder S
Front Immunol. 2023; 13:1033705.
PMID: 36591244
PMC: 9799097.
DOI: 10.3389/fimmu.2022.1033705.
The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
Maffini E, Ursi M, Barbato F, Dicataldo M, Roberto M, Campanini E
Front Oncol. 2022; 12:1066285.
PMID: 36530990
PMC: 9748414.
DOI: 10.3389/fonc.2022.1066285.
Tumour Derived Extracellular Vesicles: Challenging Target to Blunt Tumour Immune Evasion.
Lopatina T, Sarcinella A, Brizzi M
Cancers (Basel). 2022; 14(16).
PMID: 36011012
PMC: 9406972.
DOI: 10.3390/cancers14164020.
Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer.
Rossetti R, Brand H, Lima S, Furtado I, Silveira R, Fantacini D
Immunother Adv. 2022; 2(1):ltac005.
PMID: 35919489
PMC: 9327125.
DOI: 10.1093/immadv/ltac005.